Stock Ratings / Health Care / ABVC / earnings

CPHI (45) CELU (34) BCTX (41) CRVO (29) ⌘ Pro Terminal →

ABVC BioPharma Inc. (ABVC) Next Earnings Date & Expected ±12.5% Move

$1.04 -4.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

ABVC BioPharma Inc. (ABVC) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $27.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABVC)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.13 Expected Swing

MODEL EARNINGS SETUP GAUGE

ABVC Quantitative Pre-Earnings Setup: 34/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (34/100)Model Risk Weight (66/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$7.9M	-$3.0M	52%
FY 2024	2024-12-31	$509.6K	-$4.9M	-$1.8M	98%
FY 2023	2023-12-31	$152.4K	-$7.8M	-$4.2M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABVC)

✓Walkthrough of ABVC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ABVC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.97%⚡ TESTING RESISTANCE

2026-10-30O $1.02H $1.04L $1.00C $1.04VOL 20.0K

RES: $1.13SUP: $0.93SMA50: $0.99SMA200: $1.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABVC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ABVC Butterfly Map → + Track ABVC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ABVC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABVC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ABVC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABVC)

Health Care Rank #852 of 1016 ⚔️ CPHI vs ABVC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABVC vs. CPHI, CELU, BCTX, CRVO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ABVC BioPharma Inc. (ABVC) ranks #852 by composite RQD confidence (34/100, grade E) and #813 by equity capitalization ($27.8M). Within this direct 5-issuer industry benchmark cohort, ABVC leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. CPHI currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with ABVC at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ABVC ACTIVE ABVC BioPharma Inc.	E	34/100	—	—	-35.0%	-4.59%	$27.8M	Benchmark Subject
CPHI China Pharma Holdings Inc.	D	45/100	—	-3.2%	-11.4%	+4.84%	$28.0M	/cphi-vs-abvc →
CELU Celularity Inc. (Class A)	E	34/100	—	24.4%	-35.0%	-9.66%	$27.6M	/celu-vs-abvc →
BCTX BriaCell Therapeutics Corp.	D-	41/100	—	—	—	-5.43%	$28.9M	/bctx-vs-abvc →
CRVO CervoMed Inc.	E	29/100	—	—	-35.0%	-20.81%	$26.5M	/crvo-vs-abvc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001173313

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ABVC BioPharma Inc. (ABVC) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $509.6K , and -100.0% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of -$3.0M, and free cash flow of -$3.0M (-65.1% YoY). On the balance sheet, ABVC closed FY2025 with $21.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$7.9M	-$3.0M	-$3.0M	$21.1M	—
FY2024 (FY)	2024-12-31	$509.6K	-$4.9M	-$1.8M	-$1.8M	$7.5M	—
FY2023 (FY)	2023-12-31	$152.4K	-$7.8M	-$4.2M	-$4.2M	—	—

3. ABVC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABVC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ABVC BioPharma Inc. (NASDAQ: ABVC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.04 (-4.59% 1D, market cap $27.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABVC ranks #852 in composite RQD confidence.

How does ABVC compare to CPHI and CELU in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABVC carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CPHI (China Pharma Holdings Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -11.4%, cap $28.0M) and CELU (Celularity Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $27.6M). Among the 5-stock peer group, ABVC leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABVC?

Per ABVC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001173313), ABVC BioPharma Inc. generated $0 in revenue (-100.0% YoY), -$7.9M in net income, and -$3.0M in free cash flow against $21.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABVC trading relative to its 50-day, 200-day, and 52-week technical levels?

ABVC last traded at $1.04 (-4.59% on volume of 34,884 shares), positioning the stock +5.05% above its 50-day simple moving average ($0.99) and -17.46% below its 200-day simple moving average ($1.26). Across its 52-week range of $0.71 to $3.06, ABVC sits at the 14.0% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.17).